Please use this identifier to cite or link to this item:
https://scholarbank.nus.edu.sg/handle/10635/121862
Title: | HEALTH ECONOMICS OF PHARMACOGENETIC TESTING | Authors: | DONG DI | Keywords: | Health Economics, Medical Decision Making, Genetic Testing, Adverse Drug Reactions, Pharmacogenetics, Health Policy | Issue Date: | 11-Aug-2015 | Citation: | DONG DI (2015-08-11). HEALTH ECONOMICS OF PHARMACOGENETIC TESTING. ScholarBank@NUS Repository. | Abstract: | SOME COMMONLY USED MEDICATIONS CAN CAUSE A LIFE-THREATENING ADVERSE DRUG REACTION NAMED STEVENS-JOHNSON SYNDROME (SJS). THOUGH THE GENETIC RISK FACTORS HAVE BEEN WELL ESTABLISHED, ADOPTION OF PHARMACOGENETIC TESTING TO REDUCE SJS RISK IN CLINICAL CARE HAS BEEN SLOW. I CONDUCT HEALTH ECONOMIC EVALUATIONS TO INFORM CLINICAL AND REGULATORY DECISION MAKING ON WHETHER PHARMACOGENETIC TESTING SHOULD BE DONE TO REDUCE THE RISK OF SJS IN SINGAPORE. I FIRST ASSESSED THE COST-EFFECTIVENESS OF TWO PHARMACOGENETIC TESTS FROM A HEALTH SYSTEM PERSPECTIVE, AND FOUND THAT GENOTYPING EPILEPSY PATIENTS FOR HLA-B*1502 PRIOR TO CARBAMAZEPINE TREATMENT WAS HIGHLY COST-EFFECTIVE, WHEREAS GENOTYPING CHRONIC GOUT PATIENTS FOR HLA-B*5801 PRIOR TO ALLOPURINOL TREATMENT WAS NOT COST-EFFECTIVE IN SINGAPORE. I THEN MEASURED PATIENTS? PREFERENCES FOR PHARMACOGENETIC TESTING IN CHRONIC GOUT TREATMENT. RESULTS SUGGESTED THAT RISK OF SJS, COST OF GENOTYPING, COST OF GOUT TREATMENT, DOCTOR?S RECOMMENDATION AND CHOICE | URI: | http://scholarbank.nus.edu.sg/handle/10635/121862 |
Appears in Collections: | Ph.D Theses (Open) |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Dong Di Dissertation.pdf | 3.65 MB | Adobe PDF | OPEN | None | View/Download |
Page view(s)
171
checked on Jan 26, 2023
Download(s)
118
checked on Jan 26, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.